De novo parallel design, synthesis and evaluation of inhibitors against the reverse transcriptase of human immunodeficiency virus type-1 and drug-resistant variants

Journal of Medicinal Chemistry

Volumn 50, Issue 10, 2007, Pages 2370-2384

  Herschhorn, Alon ^a   Lerman, Lena ^b   Weitman, Michal ^b   Gleenberg, Iris Oz ^a   Nudelman, Abraham ^b   Hizi, Amnon ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b BAR ILAN UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 4 (3 BENZOYLPHENYL)THIAZOLE 5 CARBOXAMIDE HYDROBROMIDE; 2 AMINO 4 (3 BROMO 4 CHLOROPHENYL)THIAZOLE 5 CARBOXAMIDE HYDROBROMIDE; 2 AMINO 4 (3 CHLOROPHENYL)THIAZOLE 5 CARBOXAMIDE HYDROBROMIDE; 2 AMINO 4 (3 IODOPHENYL)THIAZOLE 5 CARBOXAMIDE HYDROBROMIDE; 3 (2 CYANOACETYL)PHENYL DIETHYL PHOSPHATE; 3 (3 BENZOYLPHENYL) 3 OXOPROPANAMIDE; 3 (3 BROMO 4 CHLOROPHENYL) 3 OXOPROPANAMIDE; 3 (3 BROMO 4 CHLOROPHENYL) 3 OXOPROPANENITRILE; 3 (3 CHLOROPHENYL) 3 OXOPROPANAMIDE; 3 (3 CHLOROPHENYL) 3 OXOPROPANENITRILE; 3 (3 IODOPHENYL) 3 OXOPROPANAMIDE; 3 (3 IODOPHENYL) 3 OXOPROPANENITRILE; 3 BENZOYL 3 OXOPROPANENITRILE; 3 PHENYL 3 OXOPROPANENITRILE; 4 (3 BENZOYLPHENYL) 1H IMIDAZOLE 5 CARBOXAMIDE; 4 (3 BROMO 4 CHLOROPHENYL) 1H IMIDAZOLE 5 CARBOXAMIDE; 4 (3 CHLOROPHENYL) 1H IMIDAZOLE 5 CARBOXAMIDE; 4 (3 IODOPHENYL) 3 OXOBUTANENITRILE; 4 (3 PHENYLPHENYL) 1H IMIDAZOLE 5 CARBOXAMIDE; 4 PHENYL 1H IMIDAZOLE 5 CARBOXAMIDE; DNA POLYMERASE; IMIDAZOLECARBOXAMIDE; NEVIRAPINE; NITRILE; PHOSPHATE; PROPIONAMIDE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; SCAFFOLD PROTEIN; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; CRYSTAL STRUCTURE; ENZYME ACTIVITY; EVALUATION; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; MOLECULAR MODEL; MUTANT; NONHUMAN; PARALLEL DESIGN; SYNTHESIS; WILD TYPE;

ANIMALS; ANTI-HIV AGENTS; BINDING SITES; BUTANONES; DNA-DIRECTED DNA POLYMERASE; DRUG DESIGN; DRUG RESISTANCE, VIRAL; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; MICE; MODELS, MOLECULAR; NEVIRAPINE; NITRILES; PROTEIN CONFORMATION; REVERSE TRANSCRIPTASE INHIBITORS; RIBONUCLEASE H, CALF THYMUS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34248997450     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0613121     Document Type: Article

References (61)

1. Coffin, J. M.; Hughes, S. H.; Varmus, H. E. Retroviruses; Cold Spring Harbor Laboratory Press: Woodbury, NY, 1997.
2. De Clercq, E. Antiviral drugs in current clinical use. J. Clin. Virol. 2004, 30, 115-133.
3. Das, K.; Lewi, P. J.; Hughes, S. H.; Arnold, E. Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors. Prog. Biophys. Mol. Biol. 2005, 88, 209-231.
4. Ren, J.; Diprose, J.; Warren, J.; Esnouf, R. M.; Bird, L. E.; Ikemizu, S.; Slater, M.; Milton, J.; Balzarini, J.; Stuart, D. I.; Stammers, D. K. Phenylethylthiazolylthiourea (PETT) non-nucleoside inhibitors of HIV-1 and HIV-2 reverse transcriptases. Structural and biochemical analyses. J. Biol. Chem. 2000, 275, 5633-5639.
5. De Clercq, E. HIV-chemotherapy and -prophylaxis: new drugs, leads and approaches. Int. J. Biochem. Cell Biol. 2004, 36, 1800-1822.
6. Sarafianos, S. G.; Das, K.; Hughes, S. H.; Arnold, E. Taking aim at a moving target: designing drugs to inhibit drug-resistant HIV-1 reverse transcriptases. Curr. Opin. Struct. Biol. 2004, 14, 716-730.
7. Clavel, F.; Hance, A. J. HIV drug resistance. N. Engl. J. Med. 2004, 350, 1023-1035.
8. Das, K.; Clark, A. D., Jr.; Lewi, P. J.; Heeres, J.; De Jonge, M. R.; Koymans, L. M.; Vinkers, H. M.; Daeyaert, F.; Ludovici, D. W.; Kukla, M. J.; De Corte, B.; Kavash, R. W.; Ho, C. Y.; Ye, H.; Lichtenstein, M. A.; Andries, K.; Pauwels, R.; De Bethune, M. P.; Boyer, P. L.; Clark, P.; Hughes, S. H.; Janssen, P. A.; Arnold, E. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem. 2004, 47, 2550-2560.
9. Masuda, N.; Yamamoto, O.; Fujii, M.; Ohgami, T.; Fujiyasu, J.; Kontani, T.; Moritomo, A.; Orita, M.; Kurihara, H.; Koga, H.; Kageyama, S.; Ohta, M.; Inoue, H.; Hatta, T.; Shintani, M.; Suzuki, H.; Sudo, K.; Shimizu, Y.; Kodama, E.; Matsuoka, M.; Fujiwara, M.; Yokota, T.; Shigeta, S.; Baba, M. Studies of non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 2: synthesis and structure-activity relationships of 2-cyano and 2-hydroxy thiazolidenebenze- nesulfonamide derivatives. Bioorg. Med. Chem. 2005, 13, 949-961.
10. Romines, K. R.; Freeman, G. A.; Schaller, L. T.; Cowan, J. R.; Gonzales, S. S.; Tidwell, J. H.; Andrews, C. W., 3rd; Stammers, D. K.; Hazen, R. J.; Ferris, R. G.; Short, S. A.; Chan, J. H.; Boone, L. R. Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor. J. Med. Chem. 2006, 49, 727-739.
11. Shoichet, B. K. Virtual screening of chemical libraries. Nature 2004, 432, 862-865.
12. Schneider, G.; Fechner, U. Computer-based de novo design of drug-like molecules. Nat. Rev. Drug Discovery 2005, 4, 649-663.
13. Mao, C.; Sudbeck, E. A.; Venkatachalam, T. K.; Uckun, F. M. Structure-based drug design of non-nucleoside inhibitors for wild-type and drug-resistant HIV reverse transcriptase. Biochem. Pharmacol. 2000, 60, 1251-1265.
14. Vinkers, H. M.; de Jonge, M. R.; Daeyaert, F. F.; Heeres, J.; Koymans, L. M.; van Lenthe, J. H.; Lewi, P. J.; Timmerman, H.; Van, Aken, K.; Janssen, P. A. SYNOPSIS: SYNthesize and OPtimize System in Silico. J. Med. Chem. 2003, 46, 2765-2773.
15. Corbett, J. W.; Ko, S. S.; Rodgers, J. D.; Jeffrey, S.; Bacheler, L. T.; Klabe, R. M.; Diamond, S.; Lai, C. M.; Rabel, S. R.; Saye, J. A.; Adams, S. P.; Trainor, G. L.; Anderson, P. S.; Erickson-Viitanen, S. K. Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type I. Antimicrob. Agents Chemother. 1999, 43, 2893-2897.
16. Ren, J.; Nichols, C.; Bird, L.; Chamberlain, P.; Weaver, K.; Short, S.; Stuart, D. I.; Stammers, D. K. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. J. Mol. Biol. 2001, 312, 795-805.
17. Cerius2 LUDI user guide: San Diego, CA. 2003.
18. Bohm, H. J. The computer program LUDI: a new method for the de novo design of enzyme inhibitors. J. Comput.-Aided Mol. Des. 1992, 6, 61-78.
19. Bohm, H. J. A novel computational tool for automated structure-based drug design. J. Mol. Recognit. 1993, 6, 131-137.
20. Venkatachalam, C. M.; Jiang, X.; Oldfield, T.; Waldman, M. LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. J. Mol. Graph. Model 2003, 21, 289-307.
21. Kortekaas, T. A.; Cerfontain, H. Aromatic sulfonation. Part 66. Sulfonation of some biphenyl derivatives. J. Chem. Soc., Perkin Trans. 2 1979, 2, 224-227.
22. Avidan, O.; Meer, M. E.; Oz, I.; Hizi, A. The processivity and fidelity of DNA synthesis exhibited by the reverse transcriptase of bovine leukemia virus. Eur. J. Biochem. 2002, 269, 859-867.
23. Loya, S.; Bakhanashvili, M.; Kashman, Y.; Hizi, A. Mechanism of inhibition of HIV reverse transcriptase by toxiusol, a novel general inhibitor of retroviral and cellular DNA polymerases. Biochemistry 1995, 34, 2260-2266.
24. Erlanson, D. A.; McDowell, R. S.; O'Brien, T. Fragment-based drug discovery. J. Med. Chem. 2004, 47, 3463-3482.
25. Maly, D. J.; Choong, I. C.; Ellman, J. A. Combinatorial target-guided ligand assembly: identification of potent subtype-selective c-Src inhibitors. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 2419-2424.
26. Pellecchia, M.; Sem, D. S.; Wuthrich, K. NMR in drug discovery. Nat. Rev. Drug Discovery 2002, 1, 211-219.
27. Tsao, D. H.; Sutherland, A. G.; Jennings, L. D.; Li, Y.; Rush, T. S., III; Alvarez, J. C.; Ding, W.; Dushin, E. G.; Dushin, R. G.; Haney, S. A.; Kenny, C. H.; Malakian, A. K.; Nilakantan, R.; Mosyak, L. Discovery of novel inhibitors of the ZipA/FtsZ complex by NMR fragment screening coupled with structure-based design. Bioorg. Med. Chem. 2006, 14, 7953-7961.
28. Hizi, A.; Hughes, S. H.; Shaharabany, M. Mutational analysis of the ribonuclease H activity of human immunodeficiency virus I reverse transcriptase. Virology 1990, 175, 575-580.
29. Veber, D. F.; Johnson, S. R.; Cheng, H. Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 2002, 45, 2615-2623.
30. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug. Delivery Rev. 2001, 46, 3-26.
31. Bohm, H. J. Prediction of binding constants of protein ligands: a fast method for the prioritization of hits obtained from de novo design or 3D database search programs. J. Comput.-Aided Mol. Des. 1998, 12, 309-323.
32. Jain, A. N. Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. J. Med. Chem. 2003, 46, 499-511.
33. Jones, S.; Selitsianos, D. A simple and effective method for phosphoryl transfer using TiCl(4) catalysis. Org. Lett. 2002, 4, 3671-3673.
34. Bumagin, N. A.; Bykov, V. V. Ligandless palladium catalyzed reactions of arylboronic acids and sodium tetraphenylborate with aryl halides in aqueous media. Tetrahedron 1997, 53, 14437-14450.
35. McElvain, S. M.; Carney, T. P. Piperidine derivatives. XVII. Local anesthetics derived from substituted piperidino alcohols. J. Am. Chem. Soc. 1946, 68, 2592-2600.
36. Beak, P.; Musick, T. J.; Chen, C. W. Does formal intramolecular transfer of an acidic deuterium to a site of halogen-lithium exchange show that lithium-halogen exchange is faster than loss of the acidic deuterium? Evidence in favor of an alternative mechanism. J. Am. Chem. Soc. 1988, 110, 3538-3542.
37. Rondestvedt, C. S., Jr. New syntheses of aromatic acid chlorides from trichloromethylarenes. 1. Reaction with sulfur dioxide. J. Org. Chem. 1976, 41, 3569-3574.
38. Pagani, G.; Baruffini, A.; Mazza, M.; Vicarini, L.; Caccialanza, G. Selective phytotoxicity of halogenated benzoic acid N,N-di-sec-butyl. Farmaco, Ed. Sci. 1973, 28, 570-589.
39. Ito, Y.; Kawaisuki, N.; Giri, B. P.; Yoshida, M.; Matsuura, T. Photochemistry of meta-substituted and para-substituted aromatic polycarbonyl compounds. J. Org. Chem. 1985, 50, 2893-2904.
40. Egle, I.; Barriault, N.; Bordeleau, M.; Drage, J.; Dube, L.; Peragine, J.; Mazzocco, L.; Arora, J.; Jarvie, K.; Tehim, A. N-(1-Benzylpyrrolidin-3-yl) arylbenzamides as potent and selective human dopamine D4 antagonists. Bioorg. Med. Chem. Lett. 2004, 14, 4847-4850.
41. Yoo, S. H. Preparation of [(iodophenyl)acetoxy]cholane derivatives as intermediates for chenodeoxycholic acid. US Patent 4,895,679, Jan 23, 1990.
42. Chen, Y.; Sieburth, S. M. A new β-keto amide synthesis. Synthesis 2002, 15, 2191-2194.
43. Goldstein, D. M.; Alfredson, T.; Bertrand, J.; Browner, M. F.; Clifford, K.; Dalrymple, S. A.; Dunn, J.; Freire-Moar, J.; Harris, S.; Labadie, S. S.; La Fargue, J.; Lapierre, J. M.; Larrabee, S.; Li, F.; Papp, E.; McWeeney, D.; Ramesha, C.; Roberts, R.; Rotstein, D.; San, Pablo, B.; Sjogren, E. B.; So, O. Y.; Talamas, F. X.; Tao, W.; Trejo, A.; Villasenor, A.; Welch, M.; Welch, T.; Weller, P.; Whiteley, P. E.; Young, K.; Zipfel, S. Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2.3-dihydroxypropoxy) phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase. J. Med. Chem. 2006, 49, 1562-1575.
44. Gao, Y.; Wang, H.; Xu, M.; Lian, H.; Pan, Y.; Shi, Y. Addition of acetonitrile anions to unsaturated systems in an ultrasonically dispersed potassium system. Org. Prep. Proced. Int. 2001, 33, 351-356.
45. Baraldi, P. G.; Romagnoli, R.; Pavani, M. G.; Nunez, Mdel, C.; Tabrizi, M. A.; Shryock, J. C.; Leung, E.; Moorman, A. R.; Uluoglu, C.; Iannotta, V.; Merighi, S.; Borea, P. A. Synthesis and biological effects of novel 2-amino-3-naphthoylthiophenes as allosteric enhancers of the Al adenosine receptor. J. Med. Chem. 2003, 46, 794-809.
46. Collin, X.; Sauleau, A.; Coulon, J. 1,2,4-Triazolo mercapto and aminonitriles as potent antifungal agents. Bioorg. Med. Chem. Lett. 2003, 13, 2601-2605.
47. Gotor, V.; Liz, R.; Testera, A. M. Preparation of N-unsubstituted b-ketoamides by Rhodococcus rhodochrous-catalyzed hydration of b-ketonitriles. Tetrahedron 2004, 60, 607-618.
48. Campi, E. M.; Jackson, W. R.; Marcuccio, S. M.; Naeslund, C. G. M. High yields of unsymmetrical biaryls via cross coupling of arylboronic acids with haloarenes using a modified Suzuki-Beletskaya procedure. J. Chem. Soc., Chem. Commun. 1994, 20, 2395.
49. Kuzma, P. C.; Brown, L. E.; Harris, T. M. Generation of the dianion of N-(trimethylsilyl)acetamide and reaction of the dianion with electrophilic reagents. J. Org. Chem. 1984, 49, 2015-2018.
50. Suzuki, H.; Shinpo, K.; Yamazaki, T.; Niwa, S.; Yokoyama, Y.; Murakami, Y. Synthetic studies of 1,2,3,4-tetrahydro-1,3,4-trioxo-b-carboline alkaloids. Heterocycles 1996, 42, 83-86.
51. Pachter, I. J.; Nemeth, P. E. Pteridines. IV. Synthesis of 2,4,6-triamino-7-phenylpteridine and related compounds through the Hofmann reaction. J. Org. Chem. 1963, 28, 1203-1206.
52. Gao, S. Improved preparation of cimetidine intermediates. Zhongguo Yiyao Gongye Zazhi 1993, 24, 135-136.
53. Kurkjy, R. P.; Brown, E. V. Preparation of thiazole Grignard reagents and thiazolyl-lithium compounds. J. Am. Chem. Soc. 1952, 74, 6260-6262.
54. Yamaguchi, K.; Tsuji, T.; Kobori, T.; Hatanaka, Y.; Goda, K. Bone formation promoters. JP11209284, August 3, 1999.
55. Katsuura, K.; Mitsuhashi, K. T. hiazole analogs of benzomorphans. III. Syntheses of 4,5,6,7,8,9-hexahydro-4,8-methano-5-methylthiazolo[4,5-c]azocine and 4,5,6,7,8,9-hexahydro-4,8-methano-5-methylthiazolo[5,4-c]azocine. Chem. Pharm. Bull. 1983, 31, 2094-2102.
56. Sevilya, Z.; Loya, S.; Adir, N.; Hizi, A. The ribonuclease H activity of the reverse transcriptases of human immunodeficiency viruses type 1 and type 2 is modulated by residue 294 of the small subunit. Nucleic Acids Res. 2003, 31, 1481-1487.
57. Hizi, A.; Tal, R.; Shaharabany, M.; Currens, M. J.; Boyd, M. R.; Hughes, S. H.; McMahon, J. B. Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitors. Antimicrob. Agents Chemother. 1993, 37, 1037-1042.
58. DeLean, A.; Munson, P. J.; Rodbard, D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am. J. Physiol. 1978, 235, E97-102.
59. Parniak, M. A.; Min, K. L.; Budihas, S. R.; Le Grice, S. F.; Beutler, J. A. A fluorescence-based high-throughput screening assay for inhibitors of human immunodeficiency virus-1 reverse transcriptase-associated ribonuclease H activity. Anal. Biochem. 2003, 322, 33-39.
60. Bakhanashvili, M.; Hizi, A. Interaction of the reverse transcriptase of human immunodeficiency virus type 1 with DNA. Biochemistry 1994, 33, 12222-12228.
61. Roehm, N. W.; Rodgers, G. H.; Hatfield, S. M.; Glasebrook, A. L. An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. J. Immunol. Methods 1991, 142, 257-265.